Neil Rowe, Head of Practice at Maulin Law takes a look at the medico-legal impact of “skinny jabs”.

The rapid rise in the use of weight-loss injections in the UK has created a convergence of clinical innovation and legal risk. Originally developed for the management of type 2 diabetes, these medications are now widely prescribed – and in some cases obtained outside traditional care pathways – for obesity management.

It is estimated that last year 1.6 million adults – 3% of the population – used them. For healthcare providers, insurers, and medical malpractice practitioners, this evolving landscape raises important questions around patient safety, standard of care, and liability exposure.

What Are weight-loss injections and what are they intended for?

Weight-loss injections primarily refer to glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and liraglutide. In the UK, these are marketed under brand names such as Wegovy (semaglutide for obesity), Ozempic (semaglutide for diabetes), and Saxenda (liraglutide). These drugs work by mimicking hormones that regulate appetite and insulin secretion, leading to reduced food intake and improved glycaemic control.

They are licensed in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) and in practice, access is through specialist NHS weight management services or private providers. However, increasing numbers of patients are sourcing these medications via online pharmacies and prescribing platforms.

There is also a growing pipeline of similar agents, including dual and triple agonists such as tirzepatide (marketed as Mounjaro). It is widely anticipated that further drugs in this class will receive UK licensing soon, expanding both therapeutic options and the potential medico-legal risk profile.

Growing popularity and media reports

Recent media coverage has significantly amplified public awareness. Reports highlighting rapid weight loss, celebrity use, and social media promotion have contributed to surging demand. At the same time, investigative journalism and professional commentary have raised concerns about:

  • Ease of access through online prescribing platforms
  • Inadequate patient screening
  • Supply shortages affecting diabetic patients

There is increasing evidence – both anecdotal and reflected in regulatory commentary – that some online providers have prescribed these medications without adequate clinical interaction. In certain cases, prescribing decisions appear to rely heavily on online questionnaires, without face-to-face or even video consultation. Such practices have been criticised by professional bodies as potentially falling below expected standards of care.

Known side effects and clinical risks

While generally considered effective, GLP-1 receptor agonists are not without risk. Common side effects include:

  • Nausea, vomiting, and diarrhoea
  • Gastrointestinal discomfort
  • Fatigue

A key issue emerging in recent clinical and medico-legal commentary is gastroparesis (delayed gastric emptying). Although these medications intentionally slow gastric emptying as part of their mechanism of action, there are increasing reports of more severe or prolonged symptoms consistent with gastroparesis, including persistent vomiting, abdominal pain, and inability to tolerate oral intake. This complication has become central to emerging litigation in other jurisdictions.

More serious, albeit less common, risks include:

  • Pancreatitis
  • Gallbladder disease
  • Hypoglycaemia (particularly when combined with other therapies)
  • Potential psychiatric effects, including mood changes

Uncertainty also remains regarding long-term safety as further data is gathered. 

Minimising risk: Practical steps for pharmacists and doctors

To mitigate the risk of complaints or claims, healthcare professionals should adopt a cautious, structured, and well-documented approach:

Robust patient assessment

  • Verify BMI, comorbidities, and obtain a full medical history
  • Independently corroborate patient-provided information where possible
  • Exercise heightened caution in remote or online consultations

Informed consent

  • Provide clear, balanced information on benefits, material risks, and reasonable alternatives
  • Specifically address gastrointestinal risks, including the possibility of gastroparesis
  • Document discussions thoroughly

Appropriate prescribing

  • Adhere to licensed indications wherever possible
  • Avoid prescribing where adequate assessment cannot be achieved

Monitoring and follow-up

  • Establish mechanisms for ongoing clinical review
  • Provide clear advice on escalation of adverse symptoms

Supply chain vigilance

  • Ensure medications are sourced from legitimate suppliers and not “counterfeit”

Clear communication

  • Manage expectations heightened by social media and avoid overstating benefits

Scope for clinical negligence and product liability claims

The expansion of use beyond traditional clinical pathways increases exposure to both clinical negligence and product liability claims.

Clinical negligence

Claims may arise where:

  • Prescribing occurs without adequate assessment, particularly in online settings
  • Risks -including gastroparesis – are not properly explained
  • Patients are not appropriately monitored
  • Adverse effects are not recognised or managed promptly

Courts are likely to scrutinise whether remote prescribing models meet the Bolam/Bolitho standards. Informed consent arguments may centre around factual causation and whether the patient even if fully informed of the risks would still have proceeded. 

Product liability

The most significant recent development is the emergence of large-scale litigation in the United States concerning GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro.

Thousands of claims have been brought and consolidated into multidistrict litigation, with allegations that manufacturers such as Novo Nordisk and Eli Lilly failed to adequately warn patients and clinicians about serious risks, particularly gastrointestinal injury and gastroparesis, over and above the anticipated nausea and discomfort. There have also been reports of visual stroke.  A central issue will be intended versus off-label use (e.g Ozempic for diabetes, Wegovy for obesity). 

Given the typical lag between widespread use, adverse event reporting, and litigation, it is likely that it will take some time before individual or group claims emerge in the UK. Should those claims arise it will be interesting to see if the focus will fall on the manufacturers rather than providers. 

Implications for insurers and brokers

Insurers and brokers should anticipate increased claims activity and consider proactive risk management strategies:

  • Policy review
    Ensure coverage reflects risks associated with remote prescribing and weight management services; exclusions might be indicated, reserving rights may be appropriate for off-label use
  • Underwriting scrutiny
    Assess clinical governance frameworks, particularly for online providers
  • Risk management support
    Promote strong consent and documentation practices
  • Education and training
    Highlight emerging risks such as gastroparesis and lessons from US litigation
  • Claims preparedness
    Develop expertise in handling claims involving novel therapies and potential group actions

What the future holds

Demand is likely to continue growing. Potential developments include:

  • Licensing of additional agents within this drug class
  • Increased regulatory oversight, particularly of online prescribing
  • Continued expansion of US litigation, influencing claimant strategies in the UK
  • The potential emergence of UK group litigation if adverse event data strengthens

Conclusion

Weight-loss injections represent a significant advance in the treatment of obesity with its associated benefits. However, their rapid adoption – particularly in private and online settings – has exposed gaps in prescribing, consent, and monitoring practices. The emergence of gastroparesis as a reported complication, alongside large-scale litigation in the United States, highlights the evolving risk landscape. UK Healthcare providers, insurers, and legal practitioners should prepare now for this developing area of clinical negligence and product liability risk.